GuidaM, StrippoliS, MauleM, et al.Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup study. ESMO Open, 2021; 6:100064.
2.
LarsabalM, MartiA, JacqueminC, et al.Vitiligo-like lesions occurring in patients receiving anti–programmed cell death-1 therapies are clinically and biologically distinct from vitiligo. J Am Acad Dermatol, 2017; 76:863–870.
3.
DoussetL, BonifaceK, SeneschalJ. Vitiligo-like lesions occurring in patients receiving anti–programmed cell death-1 therapies. G Ital Dermatol Venereol, 2019; 154:435–443.
4.
ZhangL, HaoB, GengZ, et al.Toripalimab: the first domestic anti-tumor PD-1 antibody in China. Front Immunol, 2021; 12:730666.
5.
DuanS, ZhangX, WangF, et al.Coexistence of oral mucous membrane pemphigoid and lichenoid drug reaction: a case of toripalimab-triggered and pembrolizumab-aggravated oral adverse events. Oral Surg Oral Med Oral Pathol Oral Radiol, 2021; 132:e86–e91.
6.
LiuH, GuoL, ZhangJ, et al.Glycosylation-independent binding of monoclonal antibody toripalimab to FG loop of PD-1 for tumor immune checkpoint therapy. MAbs, 2019; 11:681–690.
